Advanced Clinician Scientist
Dr. med. Jonas B. Vischedyk
Department of Hematology and Oncology
Research Focus: Investigation of selective autophagy processes in the context of targeted therapies in acute myeloid leukemia
Contact: vischedyk@med.uni-frankfurt.de
AG Brandts / Koschade
The rapid evolution of targeted therapies in Acute Myeloid Leukemia (AML) over the past years lifted the prognosis even in relapsed settings. However, acquisition of therapy resistance still remains a major therapeutic challenge.
Macroautophagy (hereafter referred to as autophagy) is a cellular pathway that allows cells to recycle cytoplasmic components under stress conditions and has been implicated in therapy resistance under certain conditions. Previous work from the AG Brandts/Koschade demonstrated that autophagy and selective autophagy (i.e. the targeted autophagic degradation of cellular components) contribute to AML disease progression and may act as a resistance mechanism towards targeted therapy.
The work of Dr. Jonas Vischedyk is directed to enhance the molecular understanding of selective autophagy processes in response to targeted therapy in AML. Methodologically, he applies CRISPR/Cas9 based screening methods, proteomic and NGS-based analyses as well as metabolic and flow cytometry assays. Ultimately, the overarching goal is to identify novel approaches to overcome acquired resistance to targeted therapies.
Find out more about the Lab Brandts / Koschade here.
